Communiqués Evolus, Inc.

Actions

EOLS

US30052C1071

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 05/08/2026			Varia. 5j.	Varia. 1 janv.
6,180 ^USD	+0,98%		+2,49%	-7,07%

05/08	Transcript : Evolus, Inc., Q2 2026 Earnings Call, Aug 05, 2026
05/08	Evolus, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

05/08	Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook	BU
04/08	Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme in Canada, Australia, and New Zealand	AQ
04/08	Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand	BU
22/07	Evolus to Report Second Quarter Financial Results on August 5, 2026	BU
10/07	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
08/07	Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality	BU
19/05	Evolus to Participate in The Jefferies Global Healthcare Conference	BU
11/05	Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe	BU
04/05	Evolus : Scientific Investor Presentation	PU
04/05	Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook	BU
14/04	Evolus to Report First Quarter Financial Results on May 4, 2026	BU
31/03	Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference	BU
20/03	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
03/03	Evolus : Investor Presentation	PU
03/03	Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026	BU
25/02	Evolus to Participate in The Leerink Partners Global Healthcare Conference	BU
17/02	Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026	BU
13/02	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
09/01	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue	BU
14/11	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05/11	Evolus Reports Third Quarter 2025 Financial Results	BU
28/10/25	Evolus to Participate in 2025 Stifel Healthcare Conference	BU
23/10/25	Evolus to Report Third Quarter Financial Results on November 5 2025	AQ
22/10/25	Evolus to Report Third Quarter Financial Results on November 5, 2025	BU
13/10/25	Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ